Moderna Inc shares jumped more than 17 percent in premarket trading after announcing that its coronavirus vaccine candidate was 95 percent effective.
The Cambridge, Massachusetts-based company also said there were no “significant” safety concerns, adding the vaccine was generally safe and well-tolerated with the majority of adverse events in participants being labeled as mild or moderate.
Side effects included pain at the injection site and, after the second dose, fatigue, muscle pain and headaches.